Amikacin
A broad-spectrum aminoglycoside antibiotic that disrupts bacterial protein synthesis by binding to the 30S ribosomal subunit, used particularly for serious gram-negative bacterial infections including those caused by organisms resistant to other aminoglycosides. It requires monitoring of blood levels and kidney function due to its potential for hearing loss and kidney toxicity.
Masse moléculaire
585,6000 g/mol
LogP
-7,90
TPSA
332,00 Ų
Règle des 5 de Lipinski
Non conforme
Aires thérapeutiques
Mécanisme d'action
Binds irreversibly to the 30S ribosomal subunit, causing misreading of mRNA codons and inhibition of translocation. This leads to production of aberrant proteins and disruption of the bacterial cell membrane.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds irreversibly to the 30S ribosomal subunit, causing misreading of mRNA codons and inhibition of translocation. This leads to production of aberrant proteins and disruption of the bacterial cell membrane.
Structure 2D
Cite this structure
Embed this structure
SMILES
NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O
InChI
InChI=1S/C22H43N5O13/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36)/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+/m0/s1
Molecular Formula
C22H43N5O13
HBD / HBA
13 / 17
Liaisons Rotatives
10
Atomes Lourds
40
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
A broad-spectrum aminoglycoside antibiotic that disrupts bacterial protein synthesis by binding to the 30S ribosomal subunit, used particularly for serious gram-negative bacterial infections including those caused by organisms resistant to other aminoglycosides. It requires monitoring of blood levels and kidney function due to its potential for hearing loss and kidney toxicity.
Binds irreversibly to the 30S ribosomal subunit, causing misreading of mRNA codons and inhibition of translocation. This leads to production of aberrant proteins and disruption of the bacterial cell membrane.
Yes, Amikacin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL177. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 37768. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="amikacin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/amikacin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/amikacin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/amikacin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="amikacin"></drugfyi-drug>